secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001171843-23-005189
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK reports Q2 2023 net loss $6.2M; cash low at $10.6M; Phase 2 gastric trial planned
--------------------------------------------------------------------------------

- Six-month 2023 net loss $11.9M ($0.35/share) vs $13.9M ($0.41) in prior year period.
- Cash $10.6M at June 30, 2023, down from $14.9M at March 31, 2023; Q2 cash used $4.1M.
- Externally funded randomized Phase 2 trial in 2L gastric cancer planned at MSKCC; IND for MiNK-215 on track for 2024.
- AgenT-797 showed 75% survival in COVID-19 ARDS patients vs 30% in-hospital controls; dosed up to 1B cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/0001171843-23-005189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/f8k_081023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer